Bei­jing on­col­o­gy biotech Avi­s­tone rais­es $140M Se­ries B for com­mer­cial­iza­tion in Chi­na, ex­pan­sion in­to US

Bei­jing-based Avi­s­tone Biotech­nol­o­gy has raised 1 bil­lion yuan, about $140 mil­lion, to bankroll com­mer­cial­iza­tion of its re­cent­ly ap­proved lung can­cer drug in Chi­na and run tri­als of oth­er as­sets.

SDIC CS Cap­i­tal and IDG Cap­i­tal co-led the Se­ries B, dis­closed Thurs­day morn­ing, which al­so in­clud­ed fund­ing from Yanchuang Cap­i­tal and Cathay Cap­i­tal. Al­so in­volved is backer Bain Cap­i­tal, which con­tributed to the biotech’s $200 mil­lion Se­ries A, an­nounced in De­cem­ber 2021 af­ter Avi­s­tone had been work­ing for more than half a dozen years un­der two dif­fer­ent en­ti­ties, as End­points News pre­vi­ous­ly re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER